Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System

Keyphrases

• Neurological Events 100%
• Neurological Effects 100%
• Adverse Event Reporting System 100%
• Tumour Necrosis Factor Inhibitor (TNFi) 100%
• Adverse Events 66%
• Etanercept 33%
• Infliximab 33%
• Naranjo Score 33%
• Tumor Necrosis Factor-α 16%
• Rheumatoid Arthritis 16%
• Adalimumab 16%
• Comorbidity 16%
• No Significant Difference 16%
• Peripheral Neuropathy 16%
• Central Nervous System 16%
• New Onset 16%
• Type 1 Diabetes Mellitus (T1DM) 16%
• Inflammatory Bowel Disease 16%
• Rheumatologic Diseases 16%
• Underlying Disease 16%
• Drug Adverse Events 16%
• IBD Patients 16%
• Adverse Exposures 16%
• Certolizumab 16%
• Alternate Explanation 16%
• Freedom of Information Act 16%
• Temporal Association 16%
• Spinal Cord Demyelination 16%
• Concomitant Medications 16%
• Scoring Tool 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 100%
• Tumor Necrosis Factor Inhibitor 100%
• Infliximab 14%
• Etanercept 14%
• Inflammatory Bowel Disease 14%
• Diseases 14%
• Tumor Necrosis Factor 7%
• Rheumatoid Arthritis 7%
• Adalimumab 7%
• Diabetes Mellitus 7%
• Neuropathy 7%
• Demyelination 7%
• Inflammatory Arthritis 7%
• Comorbidity 7%